祥生医疗(688358) - 2021 Q1 - 季度财报

Financial Performance - Operating revenue for the period was CNY 81,574,219.6, representing a year-on-year increase of 21.65%[5] - Net profit attributable to shareholders was CNY 21,801,064.66, up 34.81% from the same period last year[5] - Basic earnings per share increased to CNY 0.28, reflecting a growth of 27.27%[5] - The company reported a net profit of CNY 26,759,273.51 for Q1 2021, compared to CNY 20,606,309.21 in Q1 2020, representing a growth of 29.8%[27] - The net profit for Q1 2021 was ¥12,857,294.96, up 13.5% from ¥11,327,488.33 in Q1 2020[31] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,348,481,453.14, a decrease of 0.08% compared to the end of the previous year[5] - Current liabilities decreased to ¥103,585,723.18 from ¥129,043,028.18, indicating improved liquidity management[18] - Total liabilities decreased to CNY 194,441,681.89 in Q1 2021 from CNY 205,372,483.14 in Q4 2020, a reduction of 5.5%[23] - The company's equity attributable to shareholders increased to CNY 1,166,475,024.34 from CNY 1,153,013,949.38, reflecting a growth of 1.2%[24] Cash Flow - Cash flow from operating activities improved to a net outflow of CNY 2,045,410.33, a reduction of 17.68% compared to the same period last year[5] - The cash flow from operating activities for Q1 2021 was a net outflow of ¥2,045,410.33, an improvement from a net outflow of ¥2,484,571.17 in Q1 2020[35] - The company reported cash inflows from investment activities of ¥779,082,400.00 in Q1 2021, down from ¥1,115,807,695.40 in Q1 2020[35] - The company reported a net increase in cash and cash equivalents of 725,774,212.89 RMB, compared to an increase of 5,849,335.47 RMB in the previous year[39] Research and Development - Research and development expenses accounted for 18.17% of operating revenue, a decrease of 3.06 percentage points compared to the previous year[5] - Research and development expenses for Q1 2021 were CNY 14,819,622.00, slightly higher than CNY 14,237,357.99 in Q1 2020[27] - Research and development expenses for Q1 2021 were ¥11,765,780.76, compared to ¥10,976,207.64 in Q1 2020, reflecting a focus on innovation[31] Shareholder Information - The total number of shareholders at the end of the reporting period was 4,872[10] - The largest shareholder, Wuxi Xiangsheng Investment Co., Ltd., held 40.5% of the shares[10] Compliance and Expectations - The company reported no overdue commitments during the reporting period, reflecting strong compliance with obligations[15] - The company did not anticipate significant changes in net profit compared to the previous year, indicating stable performance expectations[15] - There were no significant updates on major events that could impact the company's operations or financials[13] Inventory and Receivables - Accounts receivable stood at ¥120,734,750.21, a slight decrease from ¥126,088,799.91 in the previous year[17] - Inventory increased to ¥91,089,346.90 from ¥84,094,450.15, reflecting a strategic buildup of stock[17] - Non-current assets totaled ¥92,664,883.67, up from ¥78,949,325.22, indicating investment in long-term growth[18]